Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Building a National CML Registry

Ehab L. Atallah, MD, Arun K Singavi, MD, Bradley Taylor, Arielle Baim, Judith Myers, Emily Giever, Joan Neuner, MD, Bronwen E. Shaw, MD PhD, Kathryn E Flynn, PhD

Blood (2019) 134 (Supplement_1): 3440.

https://doi.org/10.1182/blood-2019-130358

Published: 2019

Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA

Blood (2019) 134 (Supplement_1): 5824.

https://doi.org/10.1182/blood-2019-125997

Published: 2019

Journal Articles

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

Maureen Watt, Josh Epstein, PhD, Dennis Xuan

Blood (2018) 132 (Supplement 1): 2484.

https://doi.org/10.1182/blood-2018-99-111557

Published: 2018

Journal Articles

Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Blood (2018) 132 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2018-99-109906

Published: 2018

Journal Articles

Economics of Multiple Myeloma

Rachel Wong, BSc, MD, Jason Tay, MD

Blood (2018) 132 (Supplement 1): 4773.

https://doi.org/10.1182/blood-2018-99-110140

Published: 2018

Journal Articles

Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis

Karthik Ramasamy, Howard Thom, Vijay K. D'Souza, Vanessa Buchanan, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2018-99-112882

Published: 2018

Journal Articles

Prevalence and Predictors of Renal Impairment Among Patients with Multiple Myeloma (MM): An Analysis of Oncology Clinic Electronic Health Records Linked to Commercial Claims in the United States

Geoffrey Block, MD, Alan Fu, PhD MPH, Sally Wade, MPH, Renee Jaramillo, Sumita Bhatta, MD, Leon Raskin, PhD, Rohini K Hernandez, PhD

Blood (2018) 132 (Supplement 1): 5657.

https://doi.org/10.1182/blood-2018-99-115456

Published: 2018

Journal Articles

Autoimmune-Associated Human Leukocyte Antigen (HLA) Alleles As Risk Factors for Heparin-Induced Thrombocytopenia (HIT) Antibodies

Ray Zhang, MD PhD, Brian Duffy, MA, Vinzenz Lange, PhD, Charles S. Eby, MD, Chang Liu, MD PhD

Blood (2018) 132 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2018-99-120074

Published: 2018

Journal Articles

Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients

Damion Nero, PhD, Jessica Chung, PhD MPH, Anthony R. Mato, MD, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 4692.

https://doi.org/10.1182/blood.V130.Suppl_1.4692.4692

Published: 2017

Journal Articles

Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy

Paul G Richardson, MD, Jesus F. San Miguel, MD, Philippe Moreau, MDPhD, Roman Hajek, Meletios A. Dimopoulos, Antonio Palumbo, MD, Katarina Luptakova, MD, Tomas Skacel, MD, Shaji K Kumar, MD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 3149.

https://doi.org/10.1182/blood.V130.Suppl_1.3149.3149

Published: 2017

Journal Articles

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Sri Adapa, BSPharm, MBA, Olga Ovcinnikova, MSc, Ian Leighton, PhD, Shamika de Silva, PhD, Matthew Bending, PhD, Larisa Belyanskaya, PhD, Cosentino Lidia, PhD, Anne Myerson, MSc

Blood (2017) 130 (Supplement 1): 4929.

https://doi.org/10.1182/blood.V130.Suppl_1.4929.4929

Published: 2017

Journal Articles

Consolidative Radiation with Chemotherapy in Early Stage Classical Hodgkin Lymphoma with Unfavorable Risk: The Kentucky Experience

Zin W Myint, MD, Runa Shrestha, MD, Jaclyn Nee, Bin Huang, Eric Durbin, Stacey Slone, Amit Goldberg, Maryam Zia, Reshma Ramlal, MD, Gregory Monohan, MD, Roger H. Herzig, MD, Roger A. Fleischman, MDPhD, Gerhard Carl Hildebrandt, MD, Hayder Saeed, MD

Blood (2017) 130 (Supplement 1): 5184.

https://doi.org/10.1182/blood.V130.Suppl_1.5184.5184

Published: 2017

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison Scotch, MD MPH, Robyn M. Scherber, MD, Marlene Bruso, MS, Heidi Elizabeth Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena D. S. Fauble, MD, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M Ross, MBBS, PhD FRACP, FRCPA, Federico Sackman, MD PhD, Jean-Loup Demory, MD PhD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Jan J. Michiels, PhD, Deepti Radia, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N. Lown, MBBS, MRCP, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Wunna Swe, Jonathan O. Cullis, MD, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS, MD FRCPath, FRCP, Satareh Shekouhi, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 1641.

https://doi.org/10.1182/blood.V130.Suppl_1.1641.1641

Published: 2017

Journal Articles

Infections in Patients with Myelodysplastic Syndrome. Looking for the Escape Clause!

Cesar Gentille Sanchez, MD, Qian Qin, MD, Kai Sun, MD, Joe Ensor, PhD, Mamta Puppala, MSc, Stephen Wong, PhD, Ibrahim F. Ibrahim, MD, Lawrence Rice, MDBA, Sai Ravi Kiran Pingali, MD, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 1694.

https://doi.org/10.1182/blood.V130.Suppl_1.1694.1694

Published: 2017

Journal Articles

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy

Chadi Nabhan, MD MBA, FACP, Jessica Chung, PhD MPH, Anthony R. Mato, MD, Jonathan Kish, PhD MPH, Damion Nero, PhD

Blood (2017) 130 (Supplement 1): 2111.

https://doi.org/10.1182/blood.V130.Suppl_1.2111.2111

Published: 2017

Journal Articles

Acquired Thrombotic Thrombocytopenic Purpura and Acute Pancreatitis: Variable and Reciprocal Pathophysiologic Relationships

Qian Qin, MD, Cesar Gentille Sanchez, MD, Xinyu Nan, MD, Lawrence Rice, MDBA

Blood (2017) 130 (Supplement 1): 3637.

https://doi.org/10.1182/blood.V130.Suppl_1.3637.3637

Published: 2017

Journal Articles

Real-World Outcomes of Chemoimmunotherapy in Chronic Lymphocytic Leukemia (CLL) Clinical Practice: Results from a Decade of Practice in Helsinki 2005-2015

Vesa Lindström, MD, Tiina M Jarvinen, Juha Mehtälä, Houssem Khanfir, Rosa Juuti, Amy Leval, PhD, Marjaana Säily, MD PhD

Blood (2017) 130 (Supplement 1): 5663.

https://doi.org/10.1182/blood.V130.Suppl_1.5663.5663

Published: 2017

Journal Articles

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Jessica Chung, PhD MPH, Damion Nero, PhD, Bruce Feinberg, DO, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 3449.

https://doi.org/10.1182/blood.V130.Suppl_1.3449.3449

Published: 2017

Journal Articles

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Blood (2017) 130 (Supplement 1): 5419.

https://doi.org/10.1182/blood.V130.Suppl_1.5419.5419

Published: 2017

Journal Articles

No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era

Sean I. Tracy, MDPhD, Thomas M. Habermann, MD, Andrew L Feldman, MD, Matthew J Maurer, MS, Ahmet Dogan, Usha S Perepu, MBBS, Sergei Syrbu, MD, Stephen Ansell, MD PhD, Carrie A Thompson, MD, George J Weiner, MD, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas E. Witzig, MD, James R Cerhan, MD PhD, Brian K Link, MD

Blood (2016) 128 (22): 107.

https://doi.org/10.1182/blood.V128.22.107.107

Published: 2016

NARROW

Building a National CML Registry

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding

Economics of Multiple Myeloma

Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis

Prevalence and Predictors of Renal Impairment Among Patients with Multiple Myeloma (MM): An Analysis of Oncology Clinic Electronic Health Records Linked to Commercial Claims in the United States

Autoimmune-Associated Human Leukocyte Antigen (HLA) Alleles As Risk Factors for Heparin-Induced Thrombocytopenia (HIT) Antibodies

Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients

Real-World and Clinical Trial Data in Relapsed/Refractory Multiple Myeloma (RRMM): Evaluating Treatment Duration and Comparing Effectiveness and Efficacy

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Consolidative Radiation with Chemotherapy in Early Stage Classical Hodgkin Lymphoma with Unfavorable Risk: The Kentucky Experience

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Infections in Patients with Myelodysplastic Syndrome. Looking for the Escape Clause!

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy

Acquired Thrombotic Thrombocytopenic Purpura and Acute Pancreatitis: Variable and Reciprocal Pathophysiologic Relationships

Real-World Outcomes of Chemoimmunotherapy in Chronic Lymphocytic Leukemia (CLL) Clinical Practice: Results from a Decade of Practice in Helsinki 2005-2015

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only